history of glp 1 agonists glp-1 A timeline of GLP- discovery and clinical development. Created in Discovery of GLP-1–Based Drugs for

These medications act on hormone pathways involved in appetite signaling and metabolic regulation

Exenatide prescribing information

The capacity to develop oxidative stress, arrhythmias, and HF are all associated with, and at least partly driven by, intracellular cardiomyocyte Na + and Ca 2+ concentrations [115,116,117]

Niswender K., PiSunyer X., Buse J., et al., Weight Change With Liraglutide and Comparator Therapies: An Analysis of Seven Phase 3 Trials From the Liraglutide Diabetes Development Programme, Diabetes, Obesity & Metabolism 15 (2013): 4254

Retatrutide Research Peptide Retatrutide is a synthetic triple hormone receptor agonist peptide developed by Eli Lilly the first-in-class compound to simultaneously activate GLP-1, GIP, and glucagon receptors